Current Report Filing (8-k)
March 25 2021 - 7:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
March 25, 2021
PHIO PHARMACEUTICALS CORP.
(Exact name of registrant as specified in its
charter)
Delaware
|
|
001-36304
|
|
45-3215903
|
(State or other jurisdiction
of incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
257 Simarano Drive, Suite 101
Marlborough, Massachusetts 01752
(Address of Principal Executive Offices) (Zip
Code)
Registrant’s telephone number, including
area code: (508) 767-3861
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class of securities:
|
Trading Symbol(s):
|
Name of exchange on which registered:
|
Common Stock, par value $0.0001
|
PHIO
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 25, 2021, Phio Pharmaceuticals Corp. reported
its financial results for the period ended December 31, 2020. A copy of the press released is furnished as Exhibit 99.1 to this Current
Report on Form 8-K (the “Report”).
The information in this Item 2.02 and attached
as Exhibit 99.1 to this Report will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information
will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange
Act, unless that filing expressly incorporates this information by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
PHIO PHARMACEUTICALS CORP.
|
|
|
|
|
|
|
|
|
|
Date: March 25, 2021
|
|
|
|
By:
|
|
/s/ Gerrit Dispersyn
|
|
|
|
|
|
|
Gerrit Dispersyn
President and Chief Executive Officer
|
Phio Pharmaceuticals (NASDAQ:PHIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Phio Pharmaceuticals (NASDAQ:PHIO)
Historical Stock Chart
From Sep 2023 to Sep 2024